126 related articles for article (PubMed ID: 29304474)
1. Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
Guo Y; Hu J; Wang Y; Peng X; Min J; Wang J; Matthaiou E; Cheng Y; Sun K; Tong X; Fan Y; Zhang PJ; Kandalaft LE; Irving M; Coukos G; Li C
Eur J Cancer; 2018 Feb; 90():111-121. PubMed ID: 29304474
[TBL] [Abstract][Full Text] [Related]
2. Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer.
Li C; Wang J; Hu J; Feng Y; Hasegawa K; Peng X; Duan X; Zhao A; Mikitsh JL; Muzykantov VR; Chacko AM; Pryma DA; Dunn SM; Coukos G
Oncotarget; 2014 Aug; 5(16):6994-7012. PubMed ID: 25051365
[TBL] [Abstract][Full Text] [Related]
3. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.
Rouleau C; Curiel M; Weber W; Smale R; Kurtzberg L; Mascarello J; Berger C; Wallar G; Bagley R; Honma N; Hasegawa K; Ishida I; Kataoka S; Thurberg BL; Mehraein K; Horten B; Miller G; Teicher BA
Clin Cancer Res; 2008 Nov; 14(22):7223-36. PubMed ID: 19010839
[TBL] [Abstract][Full Text] [Related]
4. Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies.
D'Onofrio A; Gano L; Melo R; Mendes F; Oliveira MC; Denoël T; Schaefer N; Viertl D; Fierle J; Coukos G; Dunn S; Prior JO; Paulo A
Eur J Pharm Biopharm; 2021 Jan; 158():233-244. PubMed ID: 33271301
[TBL] [Abstract][Full Text] [Related]
5. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.
Rouleau C; Gianolio DA; Smale R; Roth SD; Krumbholz R; Harper J; Munroe KJ; Green TL; Horten BC; Schmid SM; Teicher BA
Mol Cancer Ther; 2015 Sep; 14(9):2081-9. PubMed ID: 26184481
[TBL] [Abstract][Full Text] [Related]
6. Characterization of TEM1/endosialin in human and murine brain tumors.
Carson-Walter EB; Winans BN; Whiteman MC; Liu Y; Jarvela S; Haapasalo H; Tyler BM; Huso DL; Johnson MD; Walter KA
BMC Cancer; 2009 Nov; 9():417. PubMed ID: 19948061
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation and Dosimetry of [
Cicone F; Denoël T; Gnesin S; Riggi N; Irving M; Jakka G; Schaefer N; Viertl D; Coukos G; Prior JO
Mol Imaging Biol; 2020 Aug; 22(4):979-991. PubMed ID: 31993928
[TBL] [Abstract][Full Text] [Related]
8. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
Yuan X; Yang M; Chen X; Zhang X; Sukhadia S; Musolino N; Bao H; Chen T; Xu C; Wang Q; Santoro S; Ricklin D; Hu J; Lin R; Yang W; Li Z; Qin W; Zhao A
Cancer Immunol Immunother; 2017 Mar; 66(3):367-378. PubMed ID: 27933426
[TBL] [Abstract][Full Text] [Related]
10. Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1.
Fierle JK; Brioschi M; de Tiani M; Wetterwald L; Atsaves V; Abram-Saliba J; Petrova TV; Coukos G; Dunn SM
Cell Rep Med; 2021 Aug; 2(8):100362. PubMed ID: 34467246
[TBL] [Abstract][Full Text] [Related]
11. Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.
Zhao A; Nunez-Cruz S; Li C; Coukos G; Siegel DL; Scholler N
J Immunol Methods; 2011 Jan; 363(2):221-32. PubMed ID: 20837020
[TBL] [Abstract][Full Text] [Related]
12. TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.
Matthaiou EI; Guo Y; Barar J; Sandaltzopoulos R; Kandalaft LE; Li C; Coukos G; Omidi Y
Bioimpacts; 2022; 12(1):65-86. PubMed ID: 35087718
[No Abstract] [Full Text] [Related]
13. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
14. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
[TBL] [Abstract][Full Text] [Related]
15. Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.
Li C; Chacko AM; Hu J; Hasegawa K; Swails J; Grasso L; El-Deiry WS; Nicolaides N; Muzykantov VR; Divgi CR; Coukos G
Cancer Biol Ther; 2014 Apr; 15(4):443-51. PubMed ID: 24553243
[TBL] [Abstract][Full Text] [Related]
16. Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling.
Rouleau C; Smale R; Fu YS; Hui G; Wang F; Hutto E; Fogle R; Jones CM; Krumbholz R; Roth S; Curiel M; Ren Y; Bagley RG; Wallar G; Miller G; Schmid S; Horten B; Teicher BA
Int J Oncol; 2011 Jul; 39(1):73-89. PubMed ID: 21537839
[TBL] [Abstract][Full Text] [Related]
17. Cell-targeting fusion constructs containing recombinant gelonin.
Lyu MA; Cao YJ; Mohamedali KA; Rosenblum MG
Methods Enzymol; 2012; 502():167-214. PubMed ID: 22208986
[TBL] [Abstract][Full Text] [Related]
18. Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration.
Tomkowicz B; Rybinski K; Foley B; Ebel W; Kline B; Routhier E; Sass P; Nicolaides NC; Grasso L; Zhou Y
Proc Natl Acad Sci U S A; 2007 Nov; 104(46):17965-70. PubMed ID: 17986615
[TBL] [Abstract][Full Text] [Related]
19. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.
Lu S; Gan L; Lu T; Zhang K; Zhang J; Wu X; Han D; Xu C; Liu S; Yang F; Qin W; Wen W
Theranostics; 2024; 14(1):379-391. PubMed ID: 38164138
[TBL] [Abstract][Full Text] [Related]
20. Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
Yuan X; Yang M; Chen X; Zhang X; Sukhadia S; Musolino N; Bao H; Chen T; Xu C; Wang Q; Santoro S; Ricklin D; Hu J; Lin R; Yang W; Li Z; Qin W; Zhao A; Scholler N; Coukos G
Cancer Immunol Immunother; 2018 Feb; 67(2):329-339. PubMed ID: 29313073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
